16 december 2024 |
|
13:05 |
Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the... |
11:04 |
Family Care Center has published promising new research on a groundbreaking treatment for patients with anxiety and major depressive disorder (MDD). The findings highlight the effectiveness of a novel sequential bilateral (SBL) repetitive... |
09:56 |
The Children's Brain Tumor Network (CBTN), a consortium of leading pediatric brain tumor research institutions, announces that it has formed a groundbreaking partnership with Day One Biopharmaceuticals (Day One), a company dedicated to developing and... |
09:15 |
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that it has completed the Phase 1 dose escalation portion... |
09:00 |
Amai Proteins, a scale-up designer of novel proteins that answer the needs of consumers and industry, has succesfullly completed world's first double-blind, random clinical trial on the effects of their proprietary hyper-sweet protein, sweelin®, on... |
08:42 |
Dr. Marlena Fejzo, HER Foundation Research Director and member of the Board of Directors, spoke at the first White House Conference on Women's Health Research this week.
For over two decades, Fejzo has worked to advance hyperemesis gravidarum (HG)... |
08:40 |
? Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical significance (p<0.0001)
? Approximately 50% of patients in BROADWAY (Obicetrapib... |
08:30 |
IceCure Medical Ltd. ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by... |
08:00 |
SIFI, a leading international ophthalmic company, announced the accomplishment of a key milestone in the pursuit of regulatory approvals in the United Kingdom ("UK") and regulatory progress for filing in the United States of... |
07:30 |
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment... |
07:30 |
BHV-1300 achieved deep lowering of targeted IgG, with reductions > 60% in the lowest subcutaneous dose tested in the MAD.Subcutaneous BHV-1300 achieved rapid and progressive lowering of IgG within hours of each weekly dose administration, and... |
07:30 |
Arthrex, a global leader in minimally invasive surgical technology, announces new research that shows its cutting-edge ACL reconstruction (ACLR) using the InternalBracetm technique offers an effective solution to combat reinjuries for young... |
07:03 |
Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics,... |
06:00 |
Nominated development candidate IDE251, a potential first-in-class KAT6/7 inhibitorIDE251 is targeted to be evaluated in breast and NSCLC with 8p11 amplification, and in the setting of lineage addiction. 8p11 amplification prevalence is projected to... |
15 december 2024 |
|
21:30 |
Harvest Integrated Research Organization (HiRO), a boutique global clinical research organization (CRO) providing cross-border clinical trial solutions, proudly announces the signing of a Memorandum of Understanding (MOU) with CHA University Bundang... |
13 december 2024 |
|
09:53 |
1nHealth, a digital patient recruitment company accelerating enrollment for clinical trials, announces the appointment of Kayt Leonard as the company's first Chief Commercial Officer (CCO). Leonard will oversee the company's commercial strategy,... |
08:11 |
The Phase 3 VIVID-1 trial evaluated the safety and efficacy of Omvoh in patients with or without prior biologic failure and was the basis for the positive opinion
VIVID-1 was the first pivotal Crohn's disease trial to show benefits in hard-to-treat... |
08:00 |
Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches to precision T cell activation, announced today that Chief Executive Officer, Zhen Su, M.D., MBA, presented a clinical update highlighting the STARt-001... |
12 december 2024 |
|
19:00 |
Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announced... |
18:20 |
On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San Antonio Breast Cancer Symposium (SABCS), RemeGen Co. Ltd. ("RemeGen") (9995.HK, 688331.SH) presented for the first time the data... |
16:52 |
... |
16:01 |
Innocan Pharma Corporation (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share... |
09:40 |
A new analysis finds that the stress of being a caregiver is associated with an increased risk of developing hypertension in 21 to 44-year-old Black women, a group known to have a higher prevalence of the condition compared to women of other racial... |
09:12 |
Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") the market leader in cannabidiol (CBD) hemp extract wellness products, is pleased to share an update on the progress of DeFloria LLC's ("DeFloria") botanical pharmaceutical... |
09:00 |
Posted electronically prior to print publication by The Journal of Bone & Joint Surgery, the retrospective study assesses one of the largest evaluated cohorts of patients who underwent lumbar total disc replacement (LTDR), demonstrating the robust... |
08:31 |
Transfer RNA-derived fragments (tRFs) are small molecules present in most organisms. tRHs or tRNA halves are generated when certain tRFs are split at specific sites by enzymes. Although tRFs carry out various biological functions, not much is known... |
08:30 |
PhaseV, a pioneer in software and machine learning (ML) for advanced clinical trial optimization, announced today it will present at the AHLI Machine Learning for Health (ML4H) 2024 Symposium, taking place on December 15-16 in Vancouver, Canada. The... |
08:15 |
The Board of Directors of the Rhode Island Life Science Hub has selected Mark A. Turco, MD, to be the organization's first President and Chief Executive Officer (CEO), the organization announced today. Dr. Turco has more than 25 years of executive... |
08:00 |
CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by the... |
08:00 |
SK bioscience, a global innovative vaccine and biotech company committed to promoting human... |
08:00 |
Intensity Therapeutics, Inc. ("Intensity" or "the Company") , a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumorally injected cancer therapies intended to kill tumors... |
08:00 |
Novellia, Inc., an AI-enabled personal health data company dedicated to... |
08:00 |
DeFloria, a joint venture between Ajna BioSciences and Charlotte's Web , reported positive results from a Phase 1 single ascending and multiple ascending dose trial of AJA001 in development for the... |
07:30 |
Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing the investigational therapy Haduviotm (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis... |
05:30 |
Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, provided an update on clinical progress and data in the Phase II program RVU120, its... |
04:40 |
ADELA, an international phase III study being conducted across multiple countries, combines elacestrant with everolimus to treat advanced ER+/HER2- breast cancer with ESR1 mutations, aiming to delay disease progression.The study was presented by... |
03:30 |
SpliceBio, a genetic medicines company pioneering Protein... |
03:25 |
Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that... |
11 december 2024 |
|
19:30 |
Laekna (2105.HK) today announced that the company will present an internally discovered preclinical candidate at the 2024 San Antonio Breast Cancer Symposium (SABCS) on December 13, 2024. The presentation will feature preclinical characterization of... |
18:55 |
A2A Pharmaceuticals, Inc. ("A2A or "the company"), a clinical-stage pioneering biopharmaceutical company focused on developing innovative cancer therapies, today announced significant progress in its clinical studies exploring TACC3 (Transforming... |
12:00 |
Ready. Set. Food!, a leader in early allergen introduction solutions, and ObvioHealth, a global leader in digital clinical trial solutions, are proud to announce the successful early recruitment of 1,100 diverse participants for the Early Allergen... |
10:15 |
GNT Pharma Co. Ltd, a late-stage pharmaceutical company founded in 1998 with offices in Seoul Korea, Italy and USA, announced today the results of its latest Phase II ('SONIC') and Phase III... |
10:01 |
The CRO Services Market is expanding rapidly as pharmaceutical and biotechnology companies increasingly outsource research and development. Contract Research Organizations (CROs) offer services like clinical trials, regulatory support, and data... |
09:53 |
- CBL-514 is the first-in-class new drug candidate for large-area fat reduction. CBL-0204 Phase 2b study, approved by the U.S. FDA and AU TGA, met all the primary and secondary efficacy endpoints in FAS (full analysis set) population and PP... |
09:25 |
NeuroSense Therapeutics Ltd. ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe... |
09:25 |
The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors using the comprehensive generative chemistry engine Chemistry42.From initiation to preclinical candidate nomination, the program spanned only 12 months,... |
08:15 |
As monotherapy, imlunestrant significantly reduced the risk of progression or death by 38% compared to standard endocrine therapy (ET) in patients with ESR1 mutations
As combination therapy, imlunestrant plus Verzenio significantly reduced the risk... |
08:01 |
Lucid Diagnostics Inc. ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. , today announced that the manuscript for its CLinical Utility of EsoGuard (CLUE)... |
08:00 |
Kazia Therapeutics Limited , an oncology-focused drug development, announced that data from two abstracts will be presented at the San Antonio Breast Cancer Symposium highlighting the activity the Company's lead product candidate, paxalisib, for the... |
08:00 |
Abstract published as part of the American Society of Hematology (ASH) Annual Meeting
Study shows Annamycin effectively targets both Cytarabine (Ara-C) and Venetoclax resistant acute myeloid leukemia (AML) cell lines from heavily pretreated... |